1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsFY26 Funding Opportunities - Antimicrobial Regulatory Science Research is sponsored by FDA Office of Infectious Diseases Research Activities. The FDA funds research proposals through its Broad Agency Announcement for the Advanced Research and Development of Regulatory Science, focusing on antimicrobial regulatory science research.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Office of Infectious Diseases Research Activities | FDA Skip to in this section menu Center for Drug Evaluation and Research (CDER) Office of Infectious Diseases Research Activities Center for Drug Evaluation and Research (CDER) An update on the Cyclospora outbreak available here . Antimicrobial Regulatory Science Research Antimicrobial drug resistance is a major threat to public health.
In March 2015, The National Action Plan for Combating Antibiotic-resistant Bacteria was developed in response to Executive Order 13676: Combating Antibiotic-Resistant Bacteria , which was issued on September 18, 2014.
The updated National Action Plan for 2020 -2025 continues to outline steps for implementing the National Strategy for Combating Antibiotic-Resistant Bacteria to address urgent and serious drug-resistant threats (bacteria and fungi) that affect people in the U.S. and around the world.
The updated Plan follows the framework of CDC’s 2019 AR Threats Report and uses the term “antibiotic” to describe antibacterial and antifungal drugs, which kill bacteria and fungi, respectively. Implementation of the National Action Plan will also support World Health Assembly resolution 67. 25 (Antimicrobial Resistance), which urges countries to take urgent action at the national, regional, and local levels to combat resistance.
The FDA’s roles in combatting antimicrobial drug resistance include: Facilitating the development of new antimicrobial drugs to treat patients; and Advancing the science of clinical trial design. The design and conduct of clinical trials to evaluate new antimicrobial drugs in patients with serious bacterial and fungal infections is challenging and therefore of particular interest for FDA’s regulatory science program.
FY 2016 - FY 2025 Office of Infectious Disease CARB Research Overview (PDF - 513 KB) National Action Plan for Combatting Antibiotic-Resistant Bacteria, 2020-2025 (PDF - 7 MB) The FDA funds research proposals through FDA’s Broad Agency Announcement for the Advanced Research and Development of Regulatory Science.
This is a competitive announcement where research proposals to facilitate antibacterial and antifungal drug development and address antibacterial and antifungal drug resistance are evaluated. Request for Proposals to Facilitate Development of Susceptibility Test Interpretive Criteria (STIC or Breakpoints) for Candida auris . Request for Proposals to Advance the Development of External Controls for Invasive Fungal Infection Trials .
Submissions are due by February 24, 2026 ORISE Fellowship Opportunities Public Meetings (Upcoming and Past) Advancing Animal Models for Antibacterial Drug Development | March 5, 2020 Current State and Further Development of Animal Models of Serious Infections Caused by Acinetobacter baumannii and Pseudomonas aeruginosa | March 1, 2017 Office of Infectious Diseases (OID) Regulatory Science Extramural Research and Development Projects
According to the current listing, eligibility includes: Researchers and organizations focused on antimicrobial regulatory science, likely including academic institutions, pharmaceutical companies, and other research entities. Confirm the full requirements in the official notice before applying.
FY26 Funding Opportunities - Antimicrobial Regulatory Science Research is funded by FDA Office of Infectious Diseases Research Activities. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
A novel provision in the May 29 OMB rewrite of 2 CFR Part 200 requires recipients of federal financial assistance to apply viewpoint-neutral terms to event services on any property they control — regardless of whether the event is federally funded. The provision lands hardest on the 3,069 county governments, the research universities that hold dispersed campus venues, and the community-based nonprofits that own meeting space. Comment deadline July 13, effective October 1. The defensive posture before then is the same regardless of how the final rule narrows scope.
Read articleARPA-H is funding the first agentic AI system that can prescribe medications, monitor patients 24/7, and manage heart disease autonomously. Here is what applicants need to know.
Read articleFive weeks after a federal judge vacated the FY2026 Continuum of Care NOFO in its entirety, HUD published a Notice of Research Justifying Additional Incentives for Certain Activities To Reduce Homelessness. It is not a NOFO and not a proposed rule — it is the administrative record HUD needs to reissue the same policy and survive the next lawsuit. Here is what the four named activities tell you about the revised competition, why the October 13 comment deadline is now the real leverage point, and what CoC leads should be building right now.
Read article